OBJECTIVE: To describe the characteristics of patients with chronic noncancer pain (CNCP) prescribed opioids by community physicians and referred to a tertiary pain clinic. DESIGN: Cross-sectional, descriptive study. SETTING: A tertiary care, hospital-based pain clinic in Toronto, Ont. PARTICIPANTS: A total of 455 consecutive patients newly referred to the pain clinic by community physicians. MAIN OUTCOME MEASURES: Data on demographic characteristics, pain ratings, and medication intake were obtained using standardized collection forms and retrospective chart review. Patients were classified by diagnosis: group 1 patients had biomedical disorders only, group 2 patients had biomedical disorders and psychological factors, and group 3 patients had psychological factors only. Patients were also categorized based on opioid use: no opioid use (NOU); low opioid use (LOU), with a daily morphine-equivalent dosage (MED) of 200 mg or less; or high opioid use (HOU), with a daily MED of more than 200 mg. RESULTS: In the general study population, 63% of patients were taking opioids, with 1 in 5 exceeding an MED of 200 mg daily. In group 1, 59% of patients used opioids and 10% had HOU; 66% of patients in groups 2 and 3 were taking opioids, with 21% and 26% classified as having HOU. The mean (SD) daily MED for groups 2 and 3 HOU patients combined was significantly higher than that of group 1 HOU patients: 575.7 (472.9) mg/d versus 284.9 (74.6) mg/d, respectively. Men were twice as likely as women to have HOU; Canadian-born patients were 3 times as likely as foreign-born patients to have HOU. Psychoactive drugs were coprescribed in 61% of LOU patients and 76% of HOU patients. Greater opioid use was associated with group 2 and 3 diagnoses, male sex, Canadian-born origin, and high pain scores. CONCLUSION: Our results indicate that male, Canadian-born CNCP patients presenting with psychological morbidity or comorbidity and reporting higher pain severity ratings were more likely to receive opioids. Additionally, many CNCP patients referred to our tertiary care pain clinic were receiving opioids in excess of a 200-mg/d MED. More studies are needed to determine which factors lead to high-dose opioid prescribing in a subset of this CNCP population.
OBJECTIVE: To describe the characteristics of patients with chronic noncancer pain (CNCP) prescribed opioids by community physicians and referred to a tertiary pain clinic. DESIGN: Cross-sectional, descriptive study. SETTING: A tertiary care, hospital-based pain clinic in Toronto, Ont. PARTICIPANTS: A total of 455 consecutive patients newly referred to the pain clinic by community physicians. MAIN OUTCOME MEASURES: Data on demographic characteristics, pain ratings, and medication intake were obtained using standardized collection forms and retrospective chart review. Patients were classified by diagnosis: group 1 patients had biomedical disorders only, group 2 patients had biomedical disorders and psychological factors, and group 3 patients had psychological factors only. Patients were also categorized based on opioid use: no opioid use (NOU); low opioid use (LOU), with a daily morphine-equivalent dosage (MED) of 200 mg or less; or high opioid use (HOU), with a daily MED of more than 200 mg. RESULTS: In the general study population, 63% of patients were taking opioids, with 1 in 5 exceeding an MED of 200 mg daily. In group 1, 59% of patients used opioids and 10% had HOU; 66% of patients in groups 2 and 3 were taking opioids, with 21% and 26% classified as having HOU. The mean (SD) daily MED for groups 2 and 3 HOU patients combined was significantly higher than that of group 1 HOU patients: 575.7 (472.9) mg/d versus 284.9 (74.6) mg/d, respectively. Men were twice as likely as women to have HOU; Canadian-born patients were 3 times as likely as foreign-born patients to have HOU. Psychoactive drugs were coprescribed in 61% of LOU patients and 76% of HOU patients. Greater opioid use was associated with group 2 and 3 diagnoses, male sex, Canadian-born origin, and high pain scores. CONCLUSION: Our results indicate that male, Canadian-born CNCP patients presenting with psychological morbidity or comorbidity and reporting higher pain severity ratings were more likely to receive opioids. Additionally, many CNCP patients referred to our tertiary care pain clinic were receiving opioids in excess of a 200-mg/d MED. More studies are needed to determine which factors lead to high-dose opioid prescribing in a subset of this CNCP population.
Authors: Diana M Tisnado; John L Adams; Honghu Liu; Cheryl L Damberg; Wen-Pin Chen; Fang Ashlee Hu; David M Carlisle; Carol M Mangione; Katherine L Kahn Journal: Med Care Date: 2006-02 Impact factor: 2.983
Authors: S Fatima Lakha; Balaji Yegneswaran; Julio C Furlan; Veronica Legnini; Keith Nicholson; Angela Mailis-Gagnon Journal: Can Fam Physician Date: 2011-03 Impact factor: 3.275
Authors: A Mailis-Gagnon; B Yegneswaran; K Nicholson; S F Lakha; M Papagapiou; A J Steiman; D Ng; T Cohodarevic; M Umana; M Zurowski Journal: Pain Res Manag Date: 2007 Impact factor: 3.037
Authors: Markus B Schumacher; Stefan Jongen; Anja Knoche; Frank Petzke; Eric F Vuurman; Mark Vollrath; Johannes G Ramaekers Journal: Psychopharmacology (Berl) Date: 2017-02-12 Impact factor: 4.530
Authors: Jennifer Maria Nelli; Keith Nicholson; S Fatima Lakha; Ada F Louffat; Luis Chapparo; Julio C Furlan; Julio Furlan; Angela Mailis-Gagnon Journal: Pain Res Manag Date: 2012 Mar-Apr Impact factor: 3.037
Authors: W Häuser; F Bock; P Engeser; G Hege-Scheuing; M Hüppe; G Lindena; C Maier; H Norda; L Radbruch; R Sabatowski; M Schäfer; M Schiltenwolf; M Schuler; H Sorgatz; T Tölle; A Willweber-Strumpf; F Petzke Journal: Schmerz Date: 2015-02 Impact factor: 1.107
Authors: Janet A Parsons; Muhammad Mamdani; Onil Bhattacharyya; Claire Marie Fortin; Magda Melo; Christina Salmon; Stavroula R Raptis; Donna Bain; Patricia O'Campo Journal: BMC Health Serv Res Date: 2011-10-20 Impact factor: 2.655
Authors: Jennifer M Hah; Yasamin Sharifzadeh; Bing M Wang; Matthew J Gillespie; Stuart B Goodman; Sean C Mackey; Ian R Carroll Journal: Pain Res Treat Date: 2015-12-31